14,360 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Potomac Fund Management Inc. ADV

Potomac Fund Management Inc. ADV bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 14,360 shares of the company's stock, valued at approximately $1,235,000. Novo Nordisk A/S accounts for approximately 1.1% of Potomac Fund Management Inc. ADV's holdings, making the stock its 22nd largest position.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVO. Trexquant Investment LP grew its stake in shares of Novo Nordisk A/S by 36.6% in the 4th quarter. Trexquant Investment LP now owns 232,246 shares of the company's stock valued at $19,978,000 after buying an additional 62,267 shares in the last quarter. May Hill Capital LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $419,000. Headlands Technologies LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $893,000. Boston Family Office LLC raised its stake in shares of Novo Nordisk A/S by 0.6% in the fourth quarter. Boston Family Office LLC now owns 44,804 shares of the company's stock valued at $3,854,000 after purchasing an additional 280 shares in the last quarter. Finally, OLD Mission Capital LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $43,275,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 6.7 %

Shares of NVO stock traded down $4.52 on Friday, reaching $62.58. 10,847,371 shares of the company were exchanged, compared to its average volume of 5,643,894. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $62.37 and a one year high of $148.15. The company has a 50-day moving average of $80.85 and a 200-day moving average of $96.50. The company has a market cap of $280.84 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 47.72%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Friday, March 21st. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research note on Monday, December 23rd. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.